HIV therapy - Human Genome Sciences
Alternative Names: CCR5-mAb; CCR5mAb004; HGS 004; HGS 101Latest Information Update: 02 Oct 2021
At a glance
- Originator Human Genome Sciences
- Class Monoclonal antibodies
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Dec 2008 Discontinued - Phase-I for HIV infections in USA (IV)
- 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events, pharmacokinetics, and Viral Infections therapeutic trials sections
- 31 Mar 2005 Phase-I clinical trials in HIV infections treatment in USA (IV-infusion)